Evidence map›Paper›PMID 35127346›Full record

ArticlePreventive medicine reports2022

Smokeless Tobacco Use and Prevalence of Cardiovascular Disease Among Males in the Population Assessment of Tobacco and Health (PATH) Study, Waves 1-4.

Georges J Nahhas, K Michael Cummings, Michael J Halenar, Eva Sharma, Anthony J Alberg, Dorothy Hatuskami, Maansi Bansal-Travers, Andrew Hyland, Diann E Gaalema, Pamela B Morris and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Preventive medicine reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 3 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 3 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Non-cigarette Tobacco Use and Stroke Among West Africans: Evidence From the SIREN Study.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2024
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 1 country.

Georges J NahhasMedical University of South Carolina, USA.
K Michael CummingsMedical University of South Carolina, USA.
Michael J HalenarWestat, USA.
Eva SharmaWestat, USA.
Anthony J AlbergUniversity of South Carolina, USA.
Dorothy HatuskamiUniversity of Minnesota, USA.
Maansi Bansal-TraversRoswell Park Comprehensive Cancer Center, USA.
Andrew HylandRoswell Park Comprehensive Cancer Center, USA.
Diann E GaalemaUniversity of Vermont, USA.
Pamela B MorrisMedical University of South Carolina, USA.
Kara DuffyCenter for Tobacco Products, U.S. Food and Drug Administration, USA.
Joanne T ChangCenter for Tobacco Products, U.S. Food and Drug Administration, USA.
Guy LagaudCenter for Tobacco Products, U.S. Food and Drug Administration, USA.
Juan C VivarCenter for Tobacco Products, U.S. Food and Drug Administration, USA.
Daniela MarshallNational Institute on Drug Abuse, National Institutes of Health, USA.
Carlos BlancoNational Institute on Drug Abuse, National Institutes of Health, USA.
Kristie A TaylorWestat, USA.
United States Food and Drug Administration · USMedical University of South Carolina · USWestat (United States) · USNational Institute on Drug Abuse · USRoswell Park Comprehensive Cancer Center · USUniversity of Minnesota · USUniversity of South Carolina · USUniversity of Vermont · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this period prevalence study is to compare the prevalence of cardiovascular disease (CVD) in current/former established smokeless tobacco (SLT) users (ever SLT users who have used the product fairly regularly) to those who were: 1) never established cigarette smokers and SLT users, and 2) current/former established exclusive cigarette smokers (have smoked at least a 100 or more cigarettes in lifetime) only, adjusting for known risk factors for CVD. Analyses included 4,703 men ≥ 40 years of age who participated in the Population Assessment of Tobacco and Health (PATH) Study, Waves: 1-4, conducted between 2013 and 2017. Current users were those using SLT products daily or on some days, whereas former users had not used SLT and/or cigarettes in the past 12 months. CVD prevalence was defined as a self-reported diagnosis of congestive heart failure, stroke, or myocardial infarction. Among current/former established SLT users, years of use defined exposure history, while pack-years defined exposure history for smokers. Adjusted odds ratios (AOR) and 95% confidence intervals (CI) were reported with trend tests to examine dose-response associations. Current/former established exclusive SLT users were not significantly more likely to have had any CVD compared to never established cigarette and SLT users (OR = 1.7 [0.8-3.7]), or current/former established exclusive cigarette smokers (OR = 0.9 [0.5-1.8]). Current/former established exclusive cigarette smokers were more likely to have had any CVD compared to those who were never established cigarette and SLT users (OR = 1.6 [1.1-2.3]).

Indexed as

Cardiovascular diseaseCigarette smokingDose–responseSmokeless tobacco

Identifiers

PMID35127346
PMCPMC8800067
OpenAlexW4200496495

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.